RBP4 Inhibitor Solid Dispersion for Retinal Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatments for visual diseases and disorders associated with retinol-binding protein 4 (RBP4), particularly those affecting the retina, such as Age-Related Macular Degeneration and Stargardt Disease, where existing therapies are inadequate in reducing RBP4 concentrations and addressing associated retinal damage.
Innovation Solution
A pharmaceutical composition comprising a compound of Formula (I), which is a solid dispersion or nanosuspension, is administered to reduce RBP4 concentrations, utilizing a dispersion polymer like HPMC-AS and a surfactant to enhance bioavailability and targeting RBP4-related visual diseases by inhibiting RBP4 transport into the retina.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat RBP4-related visual diseases, then treatment is provided, but RBP4 concentrations are not effectively reduced and retinal damage persists
Solution Approach 1:
The patent changes the chemical structure parameters of RBP4 inhibitors by modifying the core heterocyclic ring systems and substituent groups to achieve more effective RBP4 concentration reduction and retinal protection
Solution Approach 2:
The patent uses solid dispersion formulations combining the RBP4 inhibitor with excipients like HPMC-AS and surfactants to enhance bioavailability and therapeutic effectiveness
2Object-affected harmful factors
If RBP4 transport into the retina is inhibited, then retinal damage is prevented, but bioavailability of the compound must be enhanced to achieve effective concentrations
Solution Approach 1:
The patent introduces surfactants and dispersion polymers as intermediaries to facilitate the delivery and absorption of the RBP4 inhibitor, enhancing its bioavailability without compromising its retinal protective effect
Solution Approach 2:
The patent changes the physical state parameters of the compound by formulating it as a solid dispersion, which improves dissolution and bioavailability characteristics
Data Source
AI summary
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as macular degeneration and the like.